Skip to main content

Systematic Review and Meta-Analysis on the Effects of Lactulose and Rifaximin on Patient-Reported Outcomes in Hepatic Encephalopathy.

Publication ,  Journal Article
Moon, AM; Kim, HP; Jiang, Y; Lupu, G; Bissram, JS; Barritt, AS; Tapper, EB
Published in: The American journal of gastroenterology
February 2023

Patients with hepatic encephalopathy (HE) suffer from significant symptoms and impaired quality of life. Improved understanding on the potential benefits of first-line HE therapies may aid patient-provider discussions regarding expected benefits of HE treatments. We aimed to perform a systematic review to assess the effects of lactulose and rifaximin on patient-reported outcomes (PROs).We searched MEDLINE, EMBASE, and Cochrane Library databases for randomized trials or prospective cohort studies using lactulose and/or rifaximin for the management of HE and assessing changes in PRO using PRO instruments. Physician reviewers independently reviewed titles, abstracts, and full texts and extracted data independently. We performed random-effects meta-analyses to examine the effects of lactulose and rifaximin on PROs.We identified 16 studies representing 1,376 patients that met inclusion criteria. Most studies assessed treatment of covert HE. In patients with covert HE, lactulose significantly improved overall patient-reported health-related quality of life measured by the Sickness Impact Profile with an estimated pooled mean difference of 6.92 (95% confidence interval: 6.66-7.18) and showed improvements in several subscales. Conversely, rifaximin demonstrated a nonstatistically significant mean difference in the total Sickness Impact Profile of 4.76 (95% confidence interval: -4.23 to 13.76), with strong evidence of heterogeneity between these studies. Studies examining other PRO instruments showed improvements in overall health-related quality of life, social functioning, and sleep from both lactulose and rifaximin.Patients with HE treated with lactulose or rifaximin reported improvements in important PROs. These results may inform provider-patient communication and help manage patient expectations regarding the potential benefits of HE therapies.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

The American journal of gastroenterology

DOI

EISSN

1572-0241

ISSN

0002-9270

Publication Date

February 2023

Volume

118

Issue

2

Start / End Page

284 / 293

Related Subject Headings

  • Rifaximin
  • Rifamycins
  • Quality of Life
  • Prospective Studies
  • Lactulose
  • Humans
  • Hepatic Encephalopathy
  • Gastrointestinal Agents
  • Gastroenterology & Hepatology
  • Drug Therapy, Combination
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Moon, A. M., Kim, H. P., Jiang, Y., Lupu, G., Bissram, J. S., Barritt, A. S., & Tapper, E. B. (2023). Systematic Review and Meta-Analysis on the Effects of Lactulose and Rifaximin on Patient-Reported Outcomes in Hepatic Encephalopathy. The American Journal of Gastroenterology, 118(2), 284–293. https://doi.org/10.14309/ajg.0000000000002008
Moon, Andrew M., Hannah P. Kim, Yue Jiang, Gabriel Lupu, Jennifer S. Bissram, A Sidney Barritt, and Elliot B. Tapper. “Systematic Review and Meta-Analysis on the Effects of Lactulose and Rifaximin on Patient-Reported Outcomes in Hepatic Encephalopathy.The American Journal of Gastroenterology 118, no. 2 (February 2023): 284–93. https://doi.org/10.14309/ajg.0000000000002008.
Moon AM, Kim HP, Jiang Y, Lupu G, Bissram JS, Barritt AS, et al. Systematic Review and Meta-Analysis on the Effects of Lactulose and Rifaximin on Patient-Reported Outcomes in Hepatic Encephalopathy. The American journal of gastroenterology. 2023 Feb;118(2):284–93.
Moon, Andrew M., et al. “Systematic Review and Meta-Analysis on the Effects of Lactulose and Rifaximin on Patient-Reported Outcomes in Hepatic Encephalopathy.The American Journal of Gastroenterology, vol. 118, no. 2, Feb. 2023, pp. 284–93. Epmc, doi:10.14309/ajg.0000000000002008.
Moon AM, Kim HP, Jiang Y, Lupu G, Bissram JS, Barritt AS, Tapper EB. Systematic Review and Meta-Analysis on the Effects of Lactulose and Rifaximin on Patient-Reported Outcomes in Hepatic Encephalopathy. The American journal of gastroenterology. 2023 Feb;118(2):284–293.

Published In

The American journal of gastroenterology

DOI

EISSN

1572-0241

ISSN

0002-9270

Publication Date

February 2023

Volume

118

Issue

2

Start / End Page

284 / 293

Related Subject Headings

  • Rifaximin
  • Rifamycins
  • Quality of Life
  • Prospective Studies
  • Lactulose
  • Humans
  • Hepatic Encephalopathy
  • Gastrointestinal Agents
  • Gastroenterology & Hepatology
  • Drug Therapy, Combination